Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Some medtech stocks did decline in 2018, but many more increased in value.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.